Today, in @nature, we reveal PART 2 of our investigations on “What IS going on in long-term survivors of #PancreaticCancer (#PDAC)?” “Is it REALLY the immune system?” Well…more evidence here - > nature.com/articles/s4158… Thread below [1/30]

Researchers from Memorial Sloan Kettering Cancer Center analyzed a recurring genetic “hotspot” called TP53 and found that the mutated protein is not only advantageous to cancer growth but can also make a cell more noticeable to the immune system, leaving it open to attack. bit.ly/3wBkEMf

Could vaccines treat cancer? Vinod BalachandranMD explained to CNN's Dr. Sanjay Gupta how he's teamed up with BioNTech SE to use mRNA technology to try to outsmart pancreatic cancer. Click below to watch. cnn.com/videos/health/…

‘Ignored and not appreciated’: Women’s research contributions often go unrecognized go.nature.com/3OeFgS6

T-cells on their way to a tumor vs when they’re in a tumor

Happy to see our work is out! Here we studied the presence of subpeptidomes in different HLA molecules of the B7 supertype. It was a pleasure working with Iñaki Alvarez and Adrián Tirado from Universitat Autònoma de Barcelona doi.org/10.1016/j.cell…

Amazing work published in nature by my colleagues Luis Rojas and Zachary Sethna at Vinod BalachandranMD. It is an honor to be part of this team working on #mRNAvaccines in #cancer

Vaccines and cancer are in the news. On the latest episode of the Cancer Straight Talk Podcast from MSK, Drs. Vinod Balachandran (@thevinodlab) and Dmitriy Zamarin MD PhD speak with Dr. Diane Reidy-Lagunes about their research into cancer vaccines. Listen here: bit.ly/3McX8Nk

Happy and honored to have helped in such a beautiful work from @itsalyourpal and Samuel Bakhoum! Congrats 👏

Proud and happy to be featured as a #MSKPostdoc. Working in an institution such as Memorial Sloan Kettering Cancer Center is amazing. A special thanks to Melody Di Bona for the continuous and unconditional support

We announced today that the first patient has been treated in a #PDAC Ph2 clinical trial with our individualized #mRNA cancer immunotherapy candidate autogene cevumeran. investors.biontech.de/news-releases/…

Ready and excited to network in Boston at the American Society for Cell Biology and EMBO annual meeting! I will be presenting our brand new story from the Samuel Bakhoum lab on micronuclear rupture- to know more, drop by room 210B, 5.30 PM, Mon 4. 👀 Happy to chat over dinner/lunch and coffees 🙂☕️

Consejos para quien quiera empezar como IP en España. Advice for those aiming to start a group as PI in Spain --------------------------------------------- Muchos me piden consejo, que yo no pedí adecuadamente. Aquí van mis reflexiones después de 17 años de IP en Biomedicina 👇

Very interesting review by the talented Melody Di Bona about micronuclei in chromosomally unstable cancers

Everything is ready to start this #SU2CScienceSummit Can't wait to see all the amazing science that will be shared here. With @SU2CScience Charlotte Reiche, MD/PhD Martina Milighetti

Research presented by Vinod BalachandranMD at #AACR24 shows that an investigational approach to treating #pancreaticcancer w/an #mRNA-based vaccine activates immune cells that can persist in the body for up to three years after treatment in certain patients. bit.ly/3JaI7dU

I am excited to present the latest work we are doing in Vinod BalachandranMD next week at #ASGCT2024. Come by Ballroom 2 at 1.30pm on May 8th to hear about Personalized #CancerVaccines in Pancreatic Cancer.

Exciting times for cancer vaccines as mRNA leads the charge! Insights from vaccines against pathogens pave the way for personalized cancer vaccination. Charlotte Reiche, MD/PhD, Zachary Sethna, Vinod BalachandranMD, and myself discuss this and much more in our newly published review in Cancer Cell

Featured today by MSK Library: RNA vaccines for cancer: Principles to practice dx.doi.org/10.1016/j.ccel… #RNA #Vaccine #Neoantigen #Cancer Pablo Guasp Charlotte Reiche, MD/PhD Vinod BalachandranMD

Proud doesn't start beggining to describe how I feel. I am lucky to have witnessed how this idea grew trough hard work and resilience to become such an incredible and rigorous work. Can't wait to see what you come up with next Melody Di Bona